Similar articles

• CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.

  Peterson MJ, Sarges R, Aldinger CE, MacDonald DP. Peterson MJ, et al. Metabolism. 1979 Apr;28(4 Suppl 1):456-61. doi: 10.1016/0026-0495(79)90056-8. Metabolism. 1979. PMID: 122297
• The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.

  Yue DK, Hanwell MA, Satchell PM, Handelsman DJ, Turtle JR. Yue DK, et al. Metabolism. 1984 Dec;33(12):1119-22. doi: 10.1016/0026-0495(84)90097-0. Metabolism. 1984. PMID: 6438438
• The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.

  Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D. Simard-Duquesne N, et al. Metabolism. 1985 Oct;34(10):885-92. doi: 10.1016/0026-0495(85)90133-7. Metabolism. 1985. PMID: 3930915
• Aldose reductase in diabetic complications of the eye.

  Kinoshita JH, Fukushi S, Kador P, Merola LO. Kinoshita JH, et al. Metabolism. 1979 Apr;28(4 Suppl 1):462-9. doi: 10.1016/0026-0495(79)90057-x. Metabolism. 1979. PMID: 45423 Review.
• Lens aldose reductase in diabetic and galactosemic cataracts.

  Parmar NS, Ghosh MN. Parmar NS, et al. Indian J Physiol Pharmacol. 1981 Jul-Sep;25(3):193-200. Indian J Physiol Pharmacol. 1981. PMID: 6795119 Review. No abstract available.